Bayer Aktienges Ads (BAYRY) 107.6850 $BAYRY
Bayer (BAYRY) Beats on Q2 Earnings, Updates 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:10AM CDT
Bayer's (BAYRY) second-quarter 2016 core earnings of $2.34 per share topped estimates while revenues marginally missed expectations; it revised its 2016 outlook.
MON: 106.77 (+0.65), INVA: 12.87 (+1.17), ANIP: 60.60 (+0.99)
Monsanto Views Bayer's Revised Proposal as Financially Inadequate and Insufficient to Ensure Deal Certainty
BusinessWire - Tue Jul 19, 7:00AM CDT
Monsanto Company (NYSE: MON) today announced that its Board of Directors unanimously views Bayer AG's revised proposal as financially inadequate and insufficient to ensure deal certainty. Monsanto remains open to continued and constructive conversations with Bayer and other parties to assess whether a transaction that the Board believes is in the best interest of Monsanto shareowners can be realized. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 106.77 (+0.65), MS: 28.73 (-0.13)
Bayer (BAYRY) Raises Offer to Buy Monsanto to $125/Share
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 10:30AM CDT
In a bid to create a global leader in agriculture, Bayer has raised its all-cash offer to Monsanto from $122 per share to $125 per share.
MON: 106.77 (+0.65), INVA: 12.87 (+1.17)
Germany's Bayer increases offer for seed company Monsanto
By GEIR MOULSON - AP - Thu Jul 14, 12:06PM CDT
BERLIN (AP) — German drug and chemicals firm Bayer increased its offer for U.S. seed company Monsanto Co. on Thursday by $3 a share to $125, saying the move followed several weeks of private talks between the pair.
MON: 106.77 (+0.65)
Monsanto Acknowledges Revised Proposal from Bayer
BusinessWire - Thu Jul 14, 11:40AM CDT
Monsanto Company (NYSE: MON) acknowledged that it has received a revised, non-binding proposal from Bayer AG for a potential acquisition of Monsanto. The Board of Directors of Monsanto will review the proposal, in consultation with its financial and legal advisors. Monsanto will have no further comment until its Board of Directors has completed its review. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 106.77 (+0.65), MS: 28.73 (-0.13)
Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.80 (+0.19), FCSC: 1.09 (unch), BMY: 74.81 (+0.15)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), ZBH: 131.14 (+3.67), LDRH: 36.98 (-0.02), MDT: 87.63 (+0.21), TMO: 158.84 (+0.02), STJ: 83.04 (+0.38), HTWR: 57.94 (+0.05), XRAY: 64.04 (+0.94), NUVA: 62.20 (+0.18), FEIC: 106.42 (+0.12)
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
BusinessWire - Fri Jun 24, 6:00AM CDT
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company's strategic investment in CRISPR Therapeutics. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences.
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 252.95 (-2.61), PFE: 36.89 (+0.22), PRTK: 12.87 (-0.11)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 43.63 (-0.02), MON: 106.77 (+0.65), EA: 76.32 (+0.04), PFE: 36.89 (+0.22), SYY: 51.79 (-0.04), STZ: 164.63 (+1.04), XOM: 88.95 (-1.25), PEP: 108.92 (+0.79), NVDA: 57.10 (+0.92), DD: 69.17 (-0.07), PG: 85.59 (+0.78), CVX: 102.48 (+0.69), DOW: 53.67 (unch), PPG: 104.71 (-0.77), ECL: 118.38 (-0.75)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 96.29 (+0.17), GS: 158.81 (-1.72), MON: 106.77 (+0.65), JPM: 63.97 (-0.13), C: 43.81 (-0.27), WFC: 47.97 (-0.16), BAC: 14.49 (-0.19), ULTA: 261.21 (+0.73), TOL: 28.01 (-0.54), BHI: 47.83 (+1.78)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 106.77 (+0.65)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 48.69 (-0.25), SYT: 78.62 (+0.42), MON: 106.77 (+0.65), MOO: 49.13 (+0.15), VEGI: 23.57 (+0.07), IYM: 80.20 (-0.36), DD: 69.17 (-0.07), DOW: 53.67 (unch)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 106.77 (+0.65)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 49.64 (-0.54), MON: 106.77 (+0.65), PFE: 36.89 (+0.22), BAC: 14.49 (-0.19), CBS.A: 55.00 (-3.12), BA: 133.66 (+0.65), VIAB: 45.47 (-0.50), CBS: 52.22 (-1.99)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 106.77 (+0.65)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 49.64 (-0.54), MON: 106.77 (+0.65), CBS: 52.22 (-1.99)
Bayer (BAYRY) Beats on Q2 Earnings, Updates 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:10AM CDT
Bayer's (BAYRY) second-quarter 2016 core earnings of $2.34 per share topped estimates while revenues marginally missed expectations; it revised its 2016 outlook.
MON: 106.77 (+0.65), INVA: 12.87 (+1.17), ANIP: 60.60 (+0.99)
Monsanto Views Bayer's Revised Proposal as Financially Inadequate and Insufficient to Ensure Deal Certainty
BusinessWire - Tue Jul 19, 7:00AM CDT
Monsanto Company (NYSE: MON) today announced that its Board of Directors unanimously views Bayer AG's revised proposal as financially inadequate and insufficient to ensure deal certainty. Monsanto remains open to continued and constructive conversations with Bayer and other parties to assess whether a transaction that the Board believes is in the best interest of Monsanto shareowners can be realized. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 106.77 (+0.65), MS: 28.73 (-0.13)
Bayer (BAYRY) Raises Offer to Buy Monsanto to $125/Share
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 10:30AM CDT
In a bid to create a global leader in agriculture, Bayer has raised its all-cash offer to Monsanto from $122 per share to $125 per share.
MON: 106.77 (+0.65), INVA: 12.87 (+1.17)
Germany's Bayer increases offer for seed company Monsanto
By GEIR MOULSON - AP - Thu Jul 14, 12:06PM CDT
BERLIN (AP) — German drug and chemicals firm Bayer increased its offer for U.S. seed company Monsanto Co. on Thursday by $3 a share to $125, saying the move followed several weeks of private talks between the pair.
MON: 106.77 (+0.65)
Monsanto Acknowledges Revised Proposal from Bayer
BusinessWire - Thu Jul 14, 11:40AM CDT
Monsanto Company (NYSE: MON) acknowledged that it has received a revised, non-binding proposal from Bayer AG for a potential acquisition of Monsanto. The Board of Directors of Monsanto will review the proposal, in consultation with its financial and legal advisors. Monsanto will have no further comment until its Board of Directors has completed its review. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 106.77 (+0.65), MS: 28.73 (-0.13)
Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.80 (+0.19), FCSC: 1.09 (unch), BMY: 74.81 (+0.15)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), ZBH: 131.14 (+3.67), LDRH: 36.98 (-0.02), MDT: 87.63 (+0.21), TMO: 158.84 (+0.02), STJ: 83.04 (+0.38), HTWR: 57.94 (+0.05), XRAY: 64.04 (+0.94), NUVA: 62.20 (+0.18), FEIC: 106.42 (+0.12)
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
BusinessWire - Fri Jun 24, 6:00AM CDT
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company's strategic investment in CRISPR Therapeutics. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences.
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 252.95 (-2.61), PFE: 36.89 (+0.22), PRTK: 12.87 (-0.11)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 43.63 (-0.02), MON: 106.77 (+0.65), EA: 76.32 (+0.04), PFE: 36.89 (+0.22), SYY: 51.79 (-0.04), STZ: 164.63 (+1.04), XOM: 88.95 (-1.25), PEP: 108.92 (+0.79), NVDA: 57.10 (+0.92), DD: 69.17 (-0.07), PG: 85.59 (+0.78), CVX: 102.48 (+0.69), DOW: 53.67 (unch), PPG: 104.71 (-0.77), ECL: 118.38 (-0.75)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 96.29 (+0.17), GS: 158.81 (-1.72), MON: 106.77 (+0.65), JPM: 63.97 (-0.13), C: 43.81 (-0.27), WFC: 47.97 (-0.16), BAC: 14.49 (-0.19), ULTA: 261.21 (+0.73), TOL: 28.01 (-0.54), BHI: 47.83 (+1.78)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 106.77 (+0.65)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 48.69 (-0.25), SYT: 78.62 (+0.42), MON: 106.77 (+0.65), MOO: 49.13 (+0.15), VEGI: 23.57 (+0.07), IYM: 80.20 (-0.36), DD: 69.17 (-0.07), DOW: 53.67 (unch)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 106.77 (+0.65)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 49.64 (-0.54), MON: 106.77 (+0.65), PFE: 36.89 (+0.22), BAC: 14.49 (-0.19), CBS.A: 55.00 (-3.12), BA: 133.66 (+0.65), VIAB: 45.47 (-0.50), CBS: 52.22 (-1.99)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 106.77 (+0.65)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 49.64 (-0.54), MON: 106.77 (+0.65), CBS: 52.22 (-1.99)
